2023 consensus of Taiwan society of cardiology on the pharmacological treatment of chronic heart failure

Chern En Chiang, Chung Lieh Hung, Yen Wen Wu, Tsung Hsien Lin, Kwo Chang Ueng, Shih Hsien Sung, Cho Ka I. Wu, Ting Hsing Chao, Hung Ju Lin, Yen Hung Lin, Jin Long Huang, Michael Yu Chih Chen, Po Lin Lin, Tze Fan Chao, Hao Min Cheng, Ming En Liu, Tzung Dau Wang, Hung I. Yeh, Yi Heng LI., Ping Yen LiuWei Hsian Yin, I. Chang Hsieh, Chun Chieh Wang, Chen Huan Chen, Pao Hsien Chu, Shing Jong Lin, San Jou Yeh, Jiunn Lee Lin, Juey Jen Hwang, Huei Fong Hung, Wen Jone Chen, Charles Jia Yin Hou

研究成果: 雜誌貢獻文章同行評審

4 引文 斯高帕斯(Scopus)

摘要

The prevalence of heart failure is increasing, causing a tremendous burden on health care systems around the world. Although mortality rate of heart failure has been significantly reduced by several effective agents in the past 3 decades, yet it remains high in observational studies. More recently, several new classes of drugs emerged with significant efficacy in reducing mortality and hospitalization in chronic heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). To integrate these effective therapies and prioritize them in the management of Asian patients, Taiwan Society of Cardiology has recently appointed a working group to formulate a consensus of pharmacological treatment in patients with chronic heart failure. Based on most updated information, this consensus provides rationales for prioritization, rapid sequencing, and in-hospital initiation of both foundational and additional therapies for patients with chronic heart failure.

原文英語
頁(從 - 到)361-390
頁數30
期刊Acta Cardiologica Sinica
39
發行號3
DOIs
出版狀態已發佈 - 5月 2023

ASJC Scopus subject areas

  • 心臟病學與心血管醫學

指紋

深入研究「2023 consensus of Taiwan society of cardiology on the pharmacological treatment of chronic heart failure」主題。共同形成了獨特的指紋。

引用此